make ppt of newly approved drugs worldwide in last 10 year for diabetes with mechanism of action and main drawbacks
Reading File
Searching the Web
newly approved diabetes drugs worldwide 2015-2025 FDA EMA mechanism of action
Reading File
Reading Web Page
newly approved diabetes drugs mechanism of action drawbacks side effects 2015-2025
Running Command
Writing File
Running Command
Running Command
Your presentation is ready!
NewlyApproved Diabetes Drugs 2015 2025
Presentation · PPTX
What's inside (18 slides, dark navy theme):
| Slide | Content |
|---|---|
| 1 | Title slide with drug class color pills |
| 2 | At-a-Glance overview table of all approved drugs 2015–2025 |
| 3 | SGLT2 Inhibitors class intro |
| 4–6 | Empagliflozin, Canagliflozin, Dapagliflozin — mechanism + drawbacks |
| 7 | GLP-1 Receptor Agonists class intro |
| 8–10 | Dulaglutide, Semaglutide SC (Ozempic), Oral Semaglutide (Rybelsus) |
| 11 | DPP-4 Inhibitors class intro |
| 12 | Alogliptin — mechanism + drawbacks |
| 13 | Tirzepatide (Mounjaro) — first-in-class GIP/GLP-1 dual agonist |
| 14 | Teplizumab (Tzield) — T1DM disease-modifying mAb |
| 15–16 | Insulin Degludec & Insulin Icodec (once-weekly) |
| 17 | Ertugliflozin + Retatrutide (triple agonist, under review) |
| 18 | Comparative summary — best drug by clinical goal |
| 19 | Key Takeaways (5 concise clinical pearls) |
Each drug slide features a teal mechanism card and a red drawbacks card side by side, with landmark trial footnotes at the bottom.
This is a shared conversation. Sign in to Orris to start your own chat.